Characterization of bone and soft-tissue tumors with in vivo 1H MR spectroscopy: Initial results

Radiology

Volumn 232, Issue 2, 2004, Pages 599-605

  Wang, Chien Kuo ^a   Li, Chun Wei ^b   Hsieh, Tsyh Jyi ^a   Chien, Sang Hsiung ^a   Liu, Gin Chung ^a   Tsai, Kun Bow ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY   (Taiwan)

^b KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Bone neoplasms; Bone neoplasms, MR; Magnetic resonance (MR), spectroscopy; Soft tissues, MR; Soft tissues, neoplasms

Indexed keywords

CHOLINE; CONTRAST MEDIUM;

ABSCESS; ACCURACY; ADOLESCENT; ADULT; AGED; ARTICLE; BENIGN TUMOR; BONE TUMOR; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; FEMALE; GIANT CELL TUMOR; HISTOPATHOLOGY; HUMAN; IMAGE SUBTRACTION; IN VIVO STUDY; MALE; MALIGNANT NEOPLASTIC DISEASE; NERVE TUMOR; NUCLEAR MAGNETIC RESONANCE IMAGING; OSTEOSARCOMA; PRIORITY JOURNAL; PROTON NUCLEAR MAGNETIC RESONANCE; SENSITIVITY AND SPECIFICITY; SOFT TISSUE TUMOR; TUMOR LOCALIZATION; TUMOR VOLUME;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BONE AND BONES; BONE NEOPLASMS; CHOLINE; DIAGNOSIS, DIFFERENTIAL; FEMALE; HUMANS; IMAGE ENHANCEMENT; IMAGE PROCESSING, COMPUTER-ASSISTED; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; SUBTRACTION TECHNIQUE;

EID: 3242782374     PISSN: 00338419     EISSN: None     Source Type: Journal    
DOI: 10.1148/radiol.2322031441     Document Type: Article

References (38)

1. Erlemann R, Reiser MF, Peters PE, et al. Musculoskeletal neoplasms: static and dynamic Gd-DTPA-enhanced MR imaging. Radiology 1989; 171:767-773.
2. Berquist TH, Ehman RL, King BF, Hodgman CG, Ilstrup DM. Value of MR imaging in differentiating benign from malignant soft-tissue masses: study of 95 lesions. AJR Am J Roentgenol 1990; 155:1251-1255.
3. Mirowitz SA, Totty WG, Lee JK. Characterization of musculoskeletal masses using dynamic Gd-DTPA enhanced spinecho MRI. J Comput Assist Tomogr 1992; 16:120-125.
4. Verstraete KL, Dierick A, De Deene Y, et al. First-pass images of musculoskeletal lesions: a new and useful diagnostic application of dynamic contrast-enhanced MRI. Magn Reson Imaging 1994; 12:687-702.
5. Verstraete KL, De Deene Y, Roels H, Dierick A, Uyttendaele D, Kunnen M. Benign and malignant musculoskeletal lesions: dynamic contrast-enhanced MR imaging - parametric "first-pass" images depict tissue vascularization and perfusion. Radiology 1994; 192:835-843.
6. Totty WG, Murphy WA, Lee JK. Soft-tissue tumors: MR imaging. Radiology 1986; 160:135-141.
7. Crim JR, Seeger LL, Yao L, Chandnani V, Eckardt JJ. Diagnosis of soft-tissue masses with MR imaging: can benign masses be differentiated from malignant ones? Radiology 1992; 185:581-586.
8. May DA, Good RB, Smith DK, Parsons TW. MR imaging of musculoskeletal tumors and tumor mimickers with intravenous gadolinium: experience with 242 patients. Skeletal Radiol 1997; 26:2-15.
9. van der Woude HJ, Verstraete KL, Hogendoorn PC, Taminiau AH, Hermans J, Bloem JL. Musculoskeletal tumors: does fast dynamic contrast-enhanced subtraction MR imaging contribute to the characterization? Radiology 1998; 208:821-828.
10. Sundaram M, McGuire MH, Schajowicz F. Soft-tissue masses: histologic basis for decreased signal (short T2) on T2-weighted images. AJR Am J Roentgenol 1987; 148:1247-1250.
11. Pettersson H, Slone RM, Spanier S, Gillespy T 3rd, Fitzsimmons JR, Scott KN. Musculoskeletal tumors: T1 and T2 relaxation times. Radiology 1988; 167:783-785.
12. Verstraete KL, van der Woude HJ. Dynamic contrast-enhanced magnetic resonance imaging. In: De Schepper AM, ed. Imaging of soft tissue tumors. 2nd ed. Berlin, Germany: Springer-Verlag, 2001; 83-104.
13. Fletcher BD, Reddick WE, Taylor JS. Dynamic MR imaging of musculoskeletal neoplasms. Radiology 1996; 200:869-872.
14. Verstraete KL, van der Woude HJ, Hogendoorn PC, De Deene Y, Kunnen M, Bloem JL. Dynamic contrast-enhanced MRI in the musculoskeletal system. J Magn Reson Imaging 1996; 6:311-321.
15. Smith IC, Blandford DE. Diagnosis of cancer in humans by 1H NMR of tissue biopsies. Biochem Cell Biol 1998; 76:472-476.
16. Millis K, Weybright P, Campbell N, et al. Classification of human liposarcoma and lipoma using ex vivo proton NMR spectroscopy. Magn Reson Med 1999; 41:257-267.
17. Singer S. New diagnostic modalities in soft tissue sarcoma. Semin Surg Oncol 1999; 17:11-22.
18. Mukherji SK, Schiro S, Castillo M, et al. Proton MR spectroscopy of squamous cell carcinoma of the upper aerodigestive tract: in vitro characteristics. AJNR Am J Neuroradiol 1996; 17:1485-1490.
19. Mackinnon WB, Barry PA, Malycha PL, et al. Fine-needle biopsy specimens of benign breast lesions distinguished from invasive cancer ex vivo with proton MR spectroscopy. Radiology 1997; 204:661-666.
20. Oya N, Aoki J, Shinozaki T, et al. Preliminary study of proton magnetic resonance spectroscopy in bone and soft tissue tumors: an unassigned signal at 2.0-2.1 ppm may be a possible indicator of malignant neuroectodermal tumor. Radiat Med 2000; 18:193-198.
21. Negendank W. Studies of human tumors by MRS: a review. NMR Biomed 1992; 5:303-324.
22. Kvistad KA, Bakken IJ, Gribbestad IS, et al. Characterization of neoplastic and normal human breast tissues with in vivo (1)H MR spectroscopy. J Magn Reson Imaging 1999; 10:159-164.
23. Yeung DK, Cheung HS, Tse GM. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 2001; 220:40-46.
24. Gribbestad IS, Singstad TE, Nilsen G, et al. In vivo (1)H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998; 8:1191-1197.
25. 3) spatial resolution. Radiology 1996; 198:795-805.
26. Allen JR, Prost RW, Griffith OW, et al. In vivo proton (H1) magnetic resonance spectroscopy for cervical carcinoma. Am J Clin Oncol 2001; 24:522-529.
27. Gribbestad IS, Bakken IJ, Singstad TE, Kvistad KA. Determination of choline content in breast tumors with H-1 MR spectroscopy: an external standard method (abstr). In: Proceedings of the Seventh Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1999; 1587.
28. Christiansen P, Henriksen O, Stubgaard M, Gideon P, Larsson HB. In vivo quantification of brain metabolites by 1H-MRS using water as an internal standard. Magn Reson Imaging 1993; 11:107-118.
29. Sijens PE, van den Bent MJ, Nowak PJ, van Dijk P, Oudkerk M. 1H chemical shift imaging reveals loss of brain tumor choline signal after administration of Gd-contrast. Magn Reson Med 1997; 37:222-225.
30. Taylor JS, Reddick WE, Kingsley PB, Ogg RJ. Proton MRS after gadolinium contrast agent (abstr). In: Proceedings of the Society of Magnetic Resonance in Medicine and the European Society of Magnetic Resonance in Medicine and Biology. Berkeley, Calif: Society of Magnetic Resonance in Medicine, 1995; 1854.
31. Lin A, Ross BD. The effect of gadolinium on quantitative short-echo time single voxel MRS of treated and untreated brain tumors (abstr). In: Proceedings of the Eighth Meeting of the International Society for Magnetic Resonance in Medicine. Berkeley, Calif: International Society for Magnetic Resonance in Medicine, 1999; 390.
32. Miller BL. A review of chemical issues in 1-H NMR spectroscopy: n-acetyl-L-aspartate, creatine and choline. NMR Biomed 1991; 4:47-52.
33. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed 1992; 5:226-233.
34. Rand SD, Prost R, Haughton V, et al. Accuracy of single voxel proton MR spectroscopy in distinguishing neoplastic from nonneoplastic brain lesions. AJNR Am J Neuroradiol 1997; 18:1695-1704.
35. Krouwer HG, Kim TA, Rand SD, et al. Single voxel proton MR spectroscopy of nonneoplastic brain lesions suggestive of a neoplasm. AJNR Am J Neuroradiol 1998; 19:1695-1703.
36. Maheshwari SR, Mukherji SK, Neelon B, et al. The choline/creatine ratio in five benign neoplasms: comparison with squamous cell carcinoma by use of in vitro MR spectroscopy. AJNR Am J Neuroradiol 2000; 21:1930-1935.
37. Bitsch A, Bruhn H, Vougioukas V, et al. Inflammatory CNS demyelination: histopathologic correlation with in vivo quantitative proton spectroscopy. AJNR Am J Neuroradiol 1999; 20:1619-1627.
38. Sharma U, Atri S, Sharma MC, Sarkar C, Jagannathan NR. Skeletal muscle metabolism in Duchenne muscular dystrophy (DMD): an in-vitro proton NMR spectroscopy study. Magn Reson Imaging 2003; 21:145-153.